Ads
related to: keytruda cancer drug- Dosing & Administration
Learn About The ENHERTU Regimen
& Access The Patient Brochure.
- See Clinical Guidelines
Is ENHERTU An Option For Your
Patients? View Clinical Guidelines.
- Official Physician Site
See If ENHERTU Is An Option &
Access Resources For Your Practice.
- ENHERTU Access & Support
Learn About A Support Program &
Find Downloadable Resources.
- MOA Info For ENHERTU
Healthcare Professionals: Visit
Site To See How ENHERTU Works.
- Register For Updates
Request A Representative & Sign Up
For Updates To Learn Abut ENHERTU
- Dosing & Administration
Search results
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barrons.com· 6 days agoThe American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual...
Exclusive | Merck Nears $1.3 Billion Deal for Eye-Drug Company EyeBio
The Wall Street Journal· 1 day agoSuch an acquisition would steer a company known for its cancer immunotherapy, Keytruda, into the...
Roche’s Sabry retires; Duchenne drug fails confirmatory test
BioPharma Dive via Yahoo Finance· 2 days agoThe veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports By Reuters
Investing.com· 1 day agoMerck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to...
Why This Top 4% Biotech Just Catapulted To A Record High
Investor's Business Daily· 5 days agoThe Netherlands-based biotech paired its drug, petosemtamab, with Merck's (MRK) cancer blockbuster, ...
Transcenta’s Osemitamab succeeds in Phase IIa G/GEJ cancer triple combo trial
Clinical Trials Arena via Yahoo Finance· 2 days agoOsemitamab...cells through antibody-dependent cellular cytotoxicity (ADCC). G/GEJ cancer landscape...
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Zacks· 6 days agoFree Report) announced updated clinical results from a cohort of the phase II IOV-COM-202 study evaluating the combination of its recently approved cell therapy Amtagvi and Merck’s blockbuster ...
TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders
Morningstar· 3 days agoTME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME),a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment ...
News Highlights: Top Company News of the Day - Wednesday at 5 AM ET
Morningstar· 20 hours agoBHP Seeks Another Extension to $50 Billion Takeover Talks With Anglo American BHP said a further deadline extension is needed before it can reach an agreement with Anglo American on a $50 billion takeover of its London-based rival. Royal Mail
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 7 days agoEisai announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology ...
Ads
related to: keytruda cancer drug